Literature DB >> 11920184

Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

A Cortelezzi1, C Cattaneo, S Cristiani, L Duca, B Sarina, G L Deliliers, G Fiorelli, M D Cappellini.   

Abstract

INTRODUCTION: Iron overload is usually observed in patients (even untransfused) with myelodysplastic syndromes (MDS), and contributes towards the generation of low molecular weight iron complexes or non-transferrin-bound iron (NTBI), which in turn favors oxidative DNA damage and consequent apoptosis.
MATERIALS AND METHODS: Levels of NTBI and lipid peroxidation were evaluated by means of free serum malondyaldehyde (MDA) in untransfused MDS patients and we tried to correlate them with ineffective erythropoiesis, apoptosis and the pattern of in vitro growth.
RESULTS: NTBI levels were found to be significantly higher in low-risk than in high-risk MDS patients, as well as in patients with a lower myeloid/erythroid ratio. MDA was found to be uniformly higher in the MDS patients as a whole than in normal controls. The bone marrow progenitor cells in the MDS patients with high NTBI levels showed a higher degree of apoptosis, but this difference was not statistically significant. Patients with a leukemic growth pattern had lower NTBI levels than those with a non-leukemic pattern.
CONCLUSION: These data suggest that NTBI is related to the degree of ineffective erythropoiesis and that it contributes towards inducing apoptosis in MDS bone marrow precursors. The presence of leukemic growth is associated with low NTBI levels, probably due to increased iron consumption by blast cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11920184     DOI: 10.1038/sj.thj.6200028

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  21 in total

1.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

Authors:  Takamasa Nishiuchi; Yuichi Okutani; Toshikazu Fujita; Kazuya Yoshida; Hiroaki Ohnishi; Reiji Haba
Journal:  Int J Hematol       Date:  2010-02-04       Impact factor: 2.490

Review 3.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  In vivo behavior of NTBI revealed by automated quantification system.

Authors:  Satoshi Ito; Katsuya Ikuta; Daisuke Kato; Addo Lynda; Kotoe Shibusa; Noriyasu Niizeki; Yasumichi Toki; Mayumi Hatayama; Masayo Yamamoto; Motohiro Shindo; Naomi Iizuka; Yutaka Kohgo; Mikihiro Fujiya
Journal:  Int J Hematol       Date:  2016-04-16       Impact factor: 2.490

Review 5.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

6.  The effect of iron overload and chelation on erythroid differentiation.

Authors:  Kazuki Taoka; Keiki Kumano; Fumihiko Nakamura; Masataka Hosoi; Susumu Goyama; Yoichi Imai; Akira Hangaishi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2011-12-23       Impact factor: 2.490

7.  Primary shunt hyperbilirubinaemia in a large four-generation family confirming autosomal dominant genetic disorder.

Authors:  Chun-Lian Wang; Xiao-Wei Liu; Fang-Gen Lu; Xiao-Ping Wu; Chun-Hui Ouyang; Dong-Ye Yang
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

8.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

Review 9.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

10.  Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.

Authors:  Rui Cui; Robert Peter Gale; Guoqing Zhu; Zefeng Xu; Tiejun Qin; Yue Zhang; Gang Huang; Bing Li; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Shiqiang Qu; Zhijian Xiao
Journal:  Leuk Res       Date:  2014-02-10       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.